Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study

Andrew Bryant; Jan Lecouturier; Giovany Orozco-Leal; Vicky Brocklebank; Sonya Carnell; Thomas Chadwick; Sarah Dunn; Johnson Sa; David Kavanagh; Ciara A Kennedy; Michal Malina; Emma Montgomery; C R Muirhead; Yemi Oluboyede; Luke Vale; Chris Weetman; Edwin Kwan Soon Wong; Len Woodward; Neil Sheerin

doi:10.3310/gjns4701

Key Points

To assess the clinical and cost-effectiveness of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome.
Multi-centre design
Open-label methodology
Single-arm approach
Evaluation of clinical outcomes and cost-effectiveness
Assessment of eculizumab withdrawal showed potential for cost savings
Clinical outcomes after withdrawal were monitored and assessed
Findings contribute to understanding treatment strategies in atypical haemolytic uraemic syndrome

Implication

A multi-centre, open-label study evaluates the cost-effectiveness of withdrawing eculizumab in atypical haemolytic uraemic syndrome, indicating potential implications for treatment strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bryant et al. (2025) studied this question.

synapsesocial.com/papers/69a91e02d6127c7a504c1911 https://doi.org/10.3310/gjns4701

View Full Paper

Ask AI

Bookmark

Share

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study

Key Points

Implication

Discussion

Cite This Study

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study

Key Points

Implication

Discussion

Cite This Study

Keep reading

Keep reading